- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01625273
Supplementation of Infant Formula With Synbiotics
January 25, 2017 updated by: Arla Foods
Supplementation of Infant Formula With the Synbiotics (Lactobacillus Paracasei Ssp. Paracasei Strain F19 and Fructo- and Galactooligosaccharides).
The primary hypothesis is that Lactobacillus paracasei ssp.
paracasei strain F19 in an infant formula containing FOS/GOS is safe and tolerable for use in infants from 0 to 6 months.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
182
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Warsaw, Poland, 01-184
- Samodzielny Publiczny Dzieciecy Szpital Kliniczny
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 day to 4 weeks (CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- healthy infants of mothers who voluntarily resigned completely from breastfeeding
- infant age 28 days
- delivered between 38 and 42 weeks of gestation
- vaginal delivery
- birth weight > 2700 g and < 4200 g
- parent or the subject's legal representative has to speak and understand Polish
Exclusion Criteria:
- fully or partially breastfed infants
- malformations, handicaps or congenital diseases that could affect normal growth
- treatment with antibiotics
- fed infant formula with pre- and/or probiotics
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
NO_INTERVENTION: IF (Infant formula)
|
|
|
EXPERIMENTAL: IF with L. paracasei strain F19
|
Provided in an infant formula, 10^8 CFU per day from 28 days to 6 months of infant age
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Growth (body weight, length, head circumference)
Time Frame: From 28 days to 6 months
|
From 28 days to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hania Szajewska, MD, Samodzielny Publiczny Dziecięcy Szpital, Warsaw
- Principal Investigator: Jacek Witwicki, MD, Samodzielny Publiczny Dziecięcy Szpital Kliniczny, Warsaw
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (ACTUAL)
March 1, 2016
Study Completion (ACTUAL)
April 1, 2016
Study Registration Dates
First Submitted
June 19, 2012
First Submitted That Met QC Criteria
June 20, 2012
First Posted (ESTIMATE)
June 21, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
January 26, 2017
Last Update Submitted That Met QC Criteria
January 25, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- KB/205/2010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infant Formula
-
Wageningen UniversityFrieslandCampinaCompleted
-
Mead Johnson NutritionBioFortisCompleted
-
NestléCompletedInfant Formula IntolerancePhilippines
-
Xinhua Hospital, Shanghai Jiao Tong University...CompletedInfant Formula IntoleranceChina
-
NestléCompletedInfant Formula | Infant Nutritional Physiological PhenomenaSaudi Arabia
-
Sun Yat-sen UniversityCompleted
-
National Institute of Environmental Health Sciences...CompletedInfant Formula | Estrogen ActivityUnited States
-
Sun Yat-sen UniversityUnknownWell-being | Infant Formula IntoleranceChina
-
Société des Produits Nestlé (SPN)RecruitingInfant Development | Growth and Development | Infant Health | Infant Formula | Infant Nutritional Physiological PhenomenaSaudi Arabia
-
Nutricia ResearchPT Nutricia Indonesia SejahteraNot yet recruitingInfant | Gut Microbiota | Follow-on Formula | FaecesIndonesia
Clinical Trials on Lactobacillus paracasei paracasei strain F19
-
Federico II UniversityUniversity of Catanzaro; Ospedale Nuovo Regina Margherita di Roma Dr. Salvatore...CompletedGastrointestinal Symptoms | Small Intestinal OvergrowthItaly
-
University of CopenhagenLundbeck Foundation; Arla FoodsCompletedObesity | Insulin ResistanceDenmark
-
Beijing Chao Yang HospitalNot yet recruiting
-
NestléCompleted
-
Chr HansenUniversity of CopenhagenCompleted
-
Sun Yat-sen UniversityActive, not recruiting
-
Taipei Veterans General Hospital, TaiwanNot yet recruitingCognitive Change | Long COVID | Brain Fog
-
Comenius UniversityCompletedAcute Lymphoblastic Leukemia, PediatricSlovakia
-
The University of New South WalesEvolution Health Pty LtdRecruiting
-
Northumbria UniversityDuPont Nutrition and HealthCompleted